microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease

Ana Lis Moyano*, Jeffrey Steplowski, Haibo Wang, Kyung No Son, Diana I. Rapolti, Jeffrey Marshall, Vince Elackattu, Michael S. Marshall, Amy K. Hebert, Cory R. Reiter, Viviana Ulloa, Katarzyna C. Pituch, Maria I. Givogri, Q. Richard Lu, Howard L. Lipton, Ernesto R. Bongarzone

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Analysis of microRNA (miR) expression in the central nervous system white matter of SJL mice infected with the BeAn strain of Theiler's murine encephalomyelitis virus (TMEV) revealed a significant reduction of miR-219, a critical regulator of myelin assembly and repair. Restoration of miR-219 expression by intranasal administration of a synthetic miR-219 mimic before disease onset ameliorates clinical disease, reduces neurogliosis, and partially recovers motor and sensorimotor function by negatively regulating proinflammatory cytokines and virus RNA replication. Moreover, RNA sequencing of host lesions showed that miR-219 significantly downregulated two genes essential for the biosynthetic cholesterol pathway, Cyp51 (lanosterol 14-α-demethylase) and Srebf1 (sterol regulatory element-binding protein-1), and reduced cholesterol biosynthesis in infected mice and rat CG-4 glial precursor cells in culture. The change in cholesterol biosynthesis had both anti-inflammatory and anti-viral effects. Because RNA viruses hijack endoplasmic reticulum double-layered membranes to provide a platform for RNA virus replication and are dependent on endogenous pools of cholesterol, miR-219 interference with cholesterol biosynthesis interfered virus RNA replication. These findings demonstrate that miR-219 inhibits TMEV-induced demyelinating disease through its anti-inflammatory and anti-viral properties. MicroRNAs (miRs) are small noncoding RNAs that regulate a myriad of biological processes by controlling gene expression. In the latest issue of Molecular Therapy, Moyano et al. show that intranasal delivery of miR-219 in a mouse model of viral demyelination reduces neurological burden and improves life quality through anti-inflammatory and anti-viral mechanisms.

Original languageEnglish (US)
Pages (from-to)730-743
Number of pages14
JournalMolecular Therapy
Volume26
Issue number3
DOIs
StatePublished - Mar 7 2018

Funding

We thank Patricia Kallio, Zhiguo Liang, Emma Ward, Ludovic D’auria, and Danilo Ceschin for excellent technical assistance and Marina Hoffman for editorial assistance. E.R.B. was funded by NIH ( R21NS087474 ) and the National Multiple Sclerosis Society (NMSS RG 4172 ). Q.R.L. was funded by NIH ( R01NS072427 ) and the National Multiple Sclerosis Society ( NMSS-RG-1507 ). H.L.L. was funded by NIH ( NS065945 ) and Modestus Bauer Foundation grants.

Keywords

  • anti-viral
  • cholesterol
  • miRNA-219
  • microglia
  • myelin
  • oligodendrocytes
  • virus-induced demyelination

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease'. Together they form a unique fingerprint.

Cite this